Filing Flows › Comparisons › APMD vs BFRI
Apnimed vs Biofrontera: APMD and BFRI compared
Apnimed is the larger company: $12.1M of revenue in its latest quarter (Q2 2026) against $12.0M for Biofrontera (Q2 2026). Biofrontera is growing faster (+33% against -29% a year earlier). Biofrontera is more profitable, with an operating margin of -4.4% against -96.9%.
Where the money goes: APMD and BFRI
Apnimed (APMD) · Q2 2026
Apnimed, Q2 2026: revenue $12.1M (-29% year over year), operating margin -96.9%, net earnings $126M. The chart follows the revenue to costs, profit and cash.
Biofrontera (BFRI) · Q2 2026
Biofrontera, Q2 2026: revenue $12.0M (+33% year over year), operating margin -4.4%, net loss $604K, operating cash flow −$1.7M. The chart follows the revenue to costs, profit and cash.
| Apnimed (APMD) | Biofrontera (BFRI) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $12.1M | $12.0M |
| Revenue growth, Y/Y | -29% | +33% |
| Operating margin | -96.9% | -4.4% |
| Net earnings | $126M | −$604K |
| Net margin | — | -5.0% |
| Operating cash flow | — | −$1.7M |
Questions
Which is bigger, Apnimed or Biofrontera?
Apnimed is the larger company: $12.1M of revenue in its latest quarter (Q2 2026) against $12.0M for Biofrontera (Q2 2026).
Is Apnimed or Biofrontera growing faster?
Biofrontera is growing faster (+33% against -29% a year earlier).
Which is more profitable, Apnimed or Biofrontera?
Biofrontera is more profitable, with an operating margin of -4.4% against -96.9%.
More: Apnimed earnings · how Apnimed makes money · Biofrontera earnings · how Biofrontera makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Sep 8, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.